Gender-related Differences in Patients With Stage I to III Upper Tract Urothelial Carcinoma: Results From the Surveillance, Epidemiology, and End Results Database

被引:48
|
作者
Lughezzani, Giovanni
Sun, Maxine
Perrotte, Paul
Shariat, Shahrokh F.
Jeldres, Claudio
Budaus, Lars
Latour, Mathieu
Widmer, Hugues
Duclos, Alain
Benard, Francois
McCormack, Michael
Montorsi, Francesco
Karakiewicz, Pierre I.
机构
[1] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ H2X 3J4, Canada
[2] Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy
[3] Univ Montreal, Dept Urol, Montreal, PQ H2X 3J4, Canada
[4] Univ Montreal, Dept Pathol, Montreal, PQ H3C 3J7, Canada
关键词
UPPER URINARY-TRACT; TRANSITIONAL-CELL-CARCINOMA; LYMPH-NODE DISSECTION; BLADDER-CANCER; RADICAL NEPHROURETERECTOMY; PROSTATE-CANCER; DIAGNOSIS; SURVIVAL; DEATH; RECURRENCE;
D O I
10.1016/j.urology.2009.09.048
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To examine the effect of gender in upper tract urothelial carcinoma (UTUC) stage at nephroureterectomy (NU), as well as on cancer-specific mortality (CSM) after NU in patients with American Joint Committee on Cancer stages I-III UTUC. METHODS Our analyses relied on 2903 (59.9%) males and 1947 (40.1%) females who underwent an NU for pT(1-3)N(0/x)M(0) UTUC between 1988 and 2006, within 17 Surveillance, Epidemiology, and End Results registries. Univariable and multivariable logistic regression models examined the effect of gender on stage and grade distribution at NU. Subsequently, cumulative incidence plots explored the impact of gender on CSM rates, after accounting for other-cause mortality (OCM). Finally, competing-risks regression models tested the independent predictor status of gender in CSM analyses. Covariates consisted of pT stage, pN stage, tumor grade, primary tumor location, type and year of surgery, age, and race. RESULTS Relative to males, females had a higher proportion of pT(3) UTUC (43.1% vs 39%; P = .02) and a higher proportion of grade III/IV UTUC (63.8% vs 59.8%; P = .04) at NU. The female gender represented an independent predictor of pT(3) UTUC at NU (hazard ratio [HR]: 1.15; P = .03). After accounting for OCM, CSM rates in females were higher than those in males (HR: 1.18; P = .03). However, in multivariable competing-risks regression models, no statistically significant differences in survival were recorded between males and females (HR: 1.07; P = .4). CONCLUSIONS Females are more likely to have more advanced pathologic T stage and higher tumor grade at NU than males. After accounting for OCM, stage, grade, and noncancer characteristics, gender no longer affects CSM. UROLOGY 75: 321-327, 2010. Crown Copyright (C) 2010 Published by Elsevier Inc.
引用
收藏
页码:321 / 327
页数:7
相关论文
共 50 条
  • [1] A prognostic nomogram for the cancer-specific survival of patients with upper-tract urothelial carcinoma based on the Surveillance, Epidemiology, and End Results Database
    Li, Chengzhuo
    Yang, Jin
    Xu, Fengshuo
    Han, Didi
    Zheng, Shuai
    Kaaya, Rahel Elishilia
    Wang, Shengpeng
    Lyu, Jun
    BMC CANCER, 2020, 20 (01)
  • [2] A prognostic nomogram for the cancer-specific survival of patients with upper-tract urothelial carcinoma based on the Surveillance, Epidemiology, and End Results Database
    Chengzhuo Li
    Jin Yang
    Fengshuo Xu
    Didi Han
    Shuai Zheng
    Rahel Elishilia Kaaya
    Shengpeng Wang
    Jun Lyu
    BMC Cancer, 20
  • [3] Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database
    Xiang, Zhen-Fei
    Hu, Dan-Fei
    Xiong, Hua-Cai
    Li, Ming-Yao
    Zhang, Zhan-Chun
    Shen, Er-Dong
    Li, Wang-Zhong
    Xiang, Yan-Qun
    ORAL ONCOLOGY, 2021, 117
  • [4] Efficacy of cytoreductive surgery for metastatic upper tract urothelial carcinoma: a Surveillance, Epidemiology and End Results (SEER) study of 508 patients
    Hu, Haopu
    Lai, Shicong
    Ni, Runfeng
    Wang, Mingrui
    Lai, Chinhui
    Ji, Jiaxiang
    Xu, Tao
    Hu, Hao
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (06) : 983 - 993
  • [5] Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients
    Xiong, Gengyan
    Yao, Lin
    Hong, Peng
    Yang, Li
    Ci, Weimin
    Liu, Libo
    He, Qun
    Gong, Kan
    Li, Xuesong
    Zhou, Liqun
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6627 - 6639
  • [6] Metabolic Syndrome and Risk of Upper Tract Urothelial Carcinoma: A Case-Control Study From Surveillance, Epidemiology and End Results-Medicare-Linked Database
    Lu, Yi
    Zhang, Wei
    Fan, Shujun
    Liang, Zhen
    Li, Zhongjia
    Tian, Jia
    Kang, Jiaqi
    Song, Yuxuan
    Liu, Kang
    Zhou, Kechong
    Wang, Xiao
    Yang, Yongjiao
    Liu, Xiaoqiang
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [7] Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
    Shang, Shijie
    Wang, Ruiyang
    Wang, Fei
    Wu, Meng
    Chen, Dawei
    Yu, Jinming
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Prognostic nomograms for patients undergoing radical operation for stage I-III appendiceal adenocarcinoma: A surveillance, epidemiology, and end results database analysis
    Xu, Weiran
    Jia, Shenghua
    Zhang, Yangzi
    Yan, Fei
    Wang, Xinyuan
    Li, Li
    Guo, Jianying
    Liang, Jun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (07) : 1656 - 1664
  • [9] CAUTION IN THE ELIMINATION OF RADIOTHERAPY FROM THE TREATMENT OF PATIENTS WITH STAGE III CLASSICAL HODGKIN LYMPHOMA: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS DATABASE ANALYSIS
    Bates, J. E.
    Dhakal, S.
    Mazloom, A.
    Casulo, C.
    Constine, L. S.
    HAEMATOLOGICA, 2016, 101 : 21 - 21
  • [10] Epidemiology and survival of small cell carcinoma of gastrointestional tract: A Surveillance, Epidemiology, and End Results (SEER) database review.
    Kumar, Abhijeet
    Sundararajan, Srinath
    Cui, Haiyan
    Patel, Hitendra
    Elquza, Emad
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)